According to ABC News' latest report, almost 38,000 Americans are diagnosed with HIV (human immunodeficiency virus) every year. There are already treatments to prevent HIV infection. In 2012, the Food ...

A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral antiretroviral medication—known as PrEP (pre-exposure prophylaxis)—to protect themselves ...

More encouraging news has been announced about the new, twice-yearly PrEP injection currently undergoing trials. Lenacapavir is already in use as a treatment for HIV. However, pharma giant Gilead has ...

The US Food and Drug Administration has approved a form of PrEP that requires injections every two months, rather than a daily pill. PrEP, or pre-exposure prophylaxis, uses antiretroviral medications ...

A new type of PrEP injection, requiring only three injections a year, could be on the way. The FDA approved injections of cabotegravir in 2021 as a form of PrEP, to minimize the risk of acquiring HIV.

Lenacapavir, a twice-yearly injectable antiretroviral, demonstrated 100% effectiveness for preventing HIV acquisition in a large study of young cisgender women in Africa, Gilead Sciences announced ...

In a major breakthrough in the fight against new HIV transmissions, a British pharmaceutical company has announced that PrEP injections every two months have proven more effective than a once-daily ...

Laura holds a Master's in Experimental Neuroscience and a Bachelor's in Biology from Imperial College London. Her areas of expertise include health, medicine, psychology, and neuroscience. Laura holds ...

A study suggests that a new medication – taken as an injection every two months – could be more effective at preventing HIV transmissions than Truvada. Truvada was the first medication approved by the ...

Wirth is the CEO of Amida Care. Crowley is the director of the O’Neill Institute’s Center for HIV and Infectious Disease Policy at Georgetown Law. In June, a clinical trial showed that a twice-yearly ...

Twice-yearly lenacapavir (Sunlenca) substantially reduced HIV infection when used for preexposure prophylaxis (PrEP) in cisgender men and transgender or gender-nonbinary persons in the pivotal PURPOSE ...